FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive problems
admin 11th August 2017 Uncategorised 0Sun Pharma’s U.S. sales for the previous quarter dropped 42%, BeiGene is offering another follow-up public offering of $175 million and the FDA issued an 8-page Form 483 to Biocon’s sterile manufacturing plant expected to produce a Herceptin biosimilar.
More: FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s 5M public offering, Biocon plant’s extensive problems
Source: fierce